Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Fresenius is a German healthcare group that runs hospitals, makes dialysis machines and infusion products, and provides sterile compounding and other services to hospitals and patients, mostly in Europe and the United States.
Fresenius sits quietly in hospital wards and dialysis clinics around the world. It runs a chain of hospitals under its Helios brand in Germany and Spain, where it treats patients directly; and it owns Fresenius Kabi, which makes the everyday medical products hospitals burn through — infusion solutions, generic drugs, and pumps that deliver medicine into a patient's veins. Kabi also provides sterile compounding, the service of mixing up custom drug doses for patients in a clean, controlled way. Alongside those sits Fresenius Vamed, a consulting and operations partner that helps hospitals and clinics run their buildings, equipment, and services. So Fresenius earns money in two main ways: hospitals and clinics paying it for patient care and operations support, and healthcare providers paying it for the drugs, devices, and mixing services their patients need.
The crown jewel for years was Fresenius Medical Care, the world's largest dialysis company, which Fresenius used to own but has been steadily spinning off so it can focus on the rest of the group. Fresenius itself began in 1912 in Germany, but the modern machine was built by acquisitions — buying hospitals and medical suppliers until the company was the sprawling healthcare conglomerate it is today. Being a big European healthcare group is a stable but not especially glamorous business: much of the revenue is regulated, government health systems pay the bills, and margins are thin. The upside is predictability — people keep getting sick and needing treatment.
Eduard Fresenius ran a pharmacy in Germany and turned its back room into a small factory. He made injection solutions and other medicines that doctors needed in reliable, sterile form. The idea was simple: a pharmacist who understands the drugs could manufacture them better than anyone else.
When Eduard Fresenius died suddenly, the tiny company nearly died with him, down to just a few dozen employees. His foster daughter Else Fernau, who had just finished her pharmacy studies, stepped in to run it. That decision kept the business alive and set it on a completely different path.
Fresenius started selling dialysis machines made by American companies. But selling the machines meant spending time with the doctors and nurses who used them, and that gave the company the knowledge to build its own. What looked like a distribution deal turned into a front-row seat to a whole new business.
Fresenius began making its own dialysis machines in Schweinfurt. The A 2008 cut dialysis time by more than half, a huge deal for patients who spent hours hooked up to a machine. It won a gold medal at a major trade fair, and Fresenius was no longer just a seller of other people's equipment.
Fresenius listed its shares on the Frankfurt stock exchange. The company had become a proper joint stock company a few years earlier, with Else Kröner owning almost all of it. The listing gave it access to public money for the first time, which mattered for what came next.
Fresenius merged its dialysis business with National Medical Care, a big American dialysis provider, to create Fresenius Medical Care. Suddenly the company was not just selling machines and clinics supplies; it was the world's leading dialysis provider, with shares trading in both Frankfurt and New York. This was the moment Fresenius became a truly global player.
After buying Pharmacia & Upjohn's international nutrition business, Fresenius combined it with its own pharma arm to create Fresenius Kabi. The new unit became the European leader in nutrition and infusion therapy, with partners and subsidiaries around the world. Fresenius now had a second major engine alongside dialysis.
Fresenius Kabi bought an Indian oncology company, Dabur Pharma, to get into cancer drugs. Then it bought APP Pharmaceuticals in the U.S., which pushed it into the North American market and made it a global leader in injectable generics. The company kept widening its reach.
Fresenius shares hit an all-time high, and the company set its sights on buying U.S. generics maker Akorn for billions. But Akorn's results turned out to be very poor, and the deal fell apart. The stock began a long slide that lasted for years. This was the turning point where the growth story started to look shaky.
By the time Michael Sen became CEO, the share price had dropped more than 70% from its peak. He saw clearly that the company needed a fundamental reset. After years of buying and expanding, Fresenius had to figure out what it was actually good at.
Fresenius launched a new strategy built around two core businesses: Fresenius Kabi and Fresenius Helios, the hospital group. It also changed Fresenius Medical Care's legal form so the dialysis giant was no longer fully consolidated into its accounts. The message was simple: focus on what works, and stop carrying everything else.
Fresenius signed an exclusive development deal with WuXi Biologics for access to up to 37 biosimilar candidates over the next decade, the largest such development agreement the industry had seen. Combined with full ownership of mAbxience, it could roughly double the company's portfolio of marketed and pipeline molecules. This was a big bet that the Biopharma engine would keep growing well past 2030.
What makes Fresenius fragile is debt and the slow, grinding nature of hospital economics. The company has spent years trying to slim down, sell non-core pieces, and cut costs after its 2022 turnaround program. It pays a dividend and has used asset sales to reduce borrowings, so it can afford the investments its hospitals and factories need. Competition is everywhere but rarely splashy: DaVita in dialysis, big generic drugmakers, and hospital operators in the countries it serves. Fresenius doesn't win because its products are exciting. It wins because hospitals need what it sells every single day, and because scale lets it make those things cheaply and reliably.
Saved answer · last researched 6 Nov 2026